Aridis Pharmaceuticals Inc. (ARDS) financial statements (2022 and earlier)

Company profile

Business Address 983 UNIVERSITY AVENUE, BLDG. B
LOS GATOS, CA 95032
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 8,23220,89724,237
Cash and cash equivalents 8,23220,89724,237
Receivables   1,660
Capitalized contract cost 1,9731,537 
Other undisclosed current assets 2,5503,4032,450
Total current assets: 12,75525,83728,347
Noncurrent Assets
Property, plant and equipment 1,2581,0061,271
Long-term investments and receivables  9960
Long-term investments  9960
Intangible assets, net (including goodwill) 273238
Intangible assets, net (excluding goodwill) 273238
Capitalized contract cost, net 90526 
Restricted cash and investments 500  
Other noncurrent assets 487557995
Total noncurrent assets: 2,3622,1303,264
TOTAL ASSETS: 15,11727,96731,611
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,2164,7295,275
Accounts payable 1,8861,7552,331
Accrued liabilities 1,3302,9742,944
Deferred revenue 18,74814,602
Debt 439  
Contract with customer, liability22
Other liabilities 37  
Total current liabilities: 22,44019,3315,297
Noncurrent Liabilities
Long-term debt and lease obligation 276  
Long-term debt, excluding current maturities 276  
Liabilities, other than long-term debt 1,0825,000 
Deferred revenue 8545,000
Other liabilities 228  
Total noncurrent liabilities: 1,3585,000 
Total liabilities: 23,79824,3315,297
Stockholders' equity
Stockholders' equity attributable to parent (8,681)3,63626,314
Common stock 111
Additional paid in capital 114,420104,40497,401
Accumulated deficit (123,102)(100,769)(71,088)
Total stockholders' equity: (8,681)3,63626,314
TOTAL LIABILITIES AND EQUITY: 15,11727,96731,611

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
Revenues 1,0001,0222,757
Gross profit: 1,0001,0222,757
Operating expenses (23,401)(30,109)(26,874)
Operating loss: (22,401)(29,087)(24,117)
Loss from continuing operations before equity method investments, income taxes: (22,401)(29,087)(24,117)
Loss from equity method investments (9)(951)(40)
Loss before gain (loss) on sale of properties: (22,410)(30,038)(24,157)
Other undisclosed net income 773572,052
Net loss attributable to parent: (22,333)(29,681)(22,105)
Preferred stock dividends and other adjustments   (1,357)
Net loss available to common stockholders, diluted: (22,333)(29,681)(23,462)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
Net loss: (22,333)(29,681)(22,105)
Comprehensive loss, net of tax, attributable to parent: (22,333)(29,681)(22,105)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: